{"schema_version":"secwatch.filing_event.v1","accession":"0001380106-22-000003","form_type":"8-K","ticker":"RPID","cik":"0001380106","company_name":"RAPID MICRO BIOSYSTEMS, INC.","filed_at":"2022-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.218055+00:00","generated_at":"2026-06-27T19:17:33.412054+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rapid Micro Bio pre-announces Q4 rev $4.7-5.2M; FY22 outlook $27-32M","bullets":["Preliminary Q4 total revenue $4.7M-$5.2M; commercial $4.5M-$4.9M; non-commercial (BARDA) $0.2M-$0.3M.","Full year 2021 total revenue $22.8M-$23.3M; commercial $21.3M-$21.7M; placed 29 systems, validated 33.","Recurring revenue grew ~90% in Q4 vs prior-year period; 16 systems validated in Q4.","FY2022 commercial revenue outlook $27M-$32M, 25%-50% growth over preliminary FY2021 commercial revenue.","Ended 2021 with >$200M cash and investments, zero debt; COVID headwinds impacted Q4 placements."],"urls":{"canonical":"https://secwatch.observer/filing/0001380106-22-000003","json":"https://secwatch.observer/filing/0001380106-22-000003.json","markdown":"https://secwatch.observer/filing/0001380106-22-000003.md","text":"https://secwatch.observer/filing/0001380106-22-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1380106/000138010622000003/0001380106-22-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1380106/000138010622000003/c106-20220109x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T19:17:33.412054+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}